Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 33.9% in January

Virax Biolabs Group Limited (NASDAQ:VRAX) was the target of a large decrease in short interest in January. As of January 15th, there was short interest totalling 109,000 shares, a decrease of 33.9% from the December 31st total of 164,900 shares. Currently, 2.7% of the company’s stock are sold short. Based on an average daily volume of 1,800,000 shares, the days-to-cover ratio is currently 0.1 days.

Virax Biolabs Group Stock Down 12.0 %

Shares of VRAX stock opened at $1.69 on Friday. The company’s 50-day simple moving average is $2.04 and its 200-day simple moving average is $2.20. Virax Biolabs Group has a one year low of $0.60 and a one year high of $9.00.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.